Energized to co-lead OrsoBio's oversubscribed $67M Series B round alongside Woodline Partners LP and existing investors Longitude Capital, Enavate Sciences, Samsara BioCapital, Eli Lilly and Company, and NuevaBio. Congratulations to CEO G. Mani Subramanian and his team on their impressive obesity, diabetes, and metabolic medicines. https://lnkd.in/etb3X6Ra
Ascenta Capital’s Post
More Relevant Posts
-
Join this webinar to hear more around the development of GLP-1s and other incretin based therapies!
Join Martin Schain (PET Imaging Director at Antaros Medical), Tina Vilsbøll (Prof. University of Copenhagen and Research Leader at Steno Diabetes Centre) and Michael Wagner (Senior VP Dewpoint Therapeutics and co-founder of Antaros Tracer) for the upcoming webinar – The Incretin Impact: A new era in metabolic disease and obesity drug development. Find out more and register here: https://lnkd.in/dcQi5K9D #incretins #drugdevelopment #clinicaltrials
-
#VertexPharmaceuticals is set to acquire #renaldisease and #immunotherapy focused #AlpineImmuneSciences for $4.9 billion. With the addition of Alpine’s lead candidate, #povetacicept, Vertex aims to address IgA nephropathy and potentially other autoimmune renal diseases. CEO Reshma Kewalramani emphasizes the synergy between Vertex’s capabilities and Alpine’s expertise, positioning povetacicept for accelerated development and potential market entry by 2027. With an eye on revenue growth and diversification, CFO Charles Wagner outlines a promising trajectory, anticipating revenue contribution by 2028. #VertexPharma #AlpineImmuneSciences #RenalDisease #BiotechInnovation
-
TLDR Biotech for May 15 - 16 Featuring: BMS lands new CAR-T accelerated approval, Roche's $2.7B obesity bet has early win, Eli Lilly leads in revenue growth, and J&J pays $850M for atopic dermatitis biotech. Read all the updates in the link below ⬇️ #pharmanews #biotechnews #tldrbiotech
-
-
Explore the latest trends and breakthroughs on the obesity therapeutics scene in this month's #LifeSciencesAffectsUsAll newsletter! 🗞️ Featuring Eli Lilly and Novo Nordisk (plus many more!), catch up on the latest clinical trials, major investments, and key partnerships in the space. 💫 #ObesityTherapies #HealthInnovation #ClinicalTrials #LifeSciencesNews
Inside Obesity Therapeutics: Trends, Triumphs and Tough Questions
-
Listen to the latest episode of Unseen Upside: Investments Beyond Their Returns, available now. In it, we explore the global obesity epidemic, how new GLP-1 drugs are offering hope to millions, and what the next generation of these therapeutics could look like. We also follow one woman’s journey to lose weight in an effort to prevent and manage the chronic conditions associated with obesity. Listen here: https://ow.ly/OPha50QZx9R
-
-
Listen to the latest episode of Unseen Upside: Investments Beyond Their Returns, available now. In it, we explore the global obesity epidemic, how new GLP-1 drugs are offering hope to millions, and what the next generation of these therapeutics could look like. We also follow one woman’s journey to lose weight in an effort to prevent and manage the chronic conditions associated with obesity. Listen here: https://ow.ly/zuQN50R4a1P
-
-
Listen to the latest episode of Unseen Upside: Investments Beyond Their Returns, available now. In it, we explore the global obesity epidemic, how new GLP-1 drugs are offering hope to millions, and what the next generation of these therapeutics could look like. We also follow one woman’s journey to lose weight in an effort to prevent and manage the chronic conditions associated with obesity. Listen here: https://ow.ly/YmKF50QXjYw
-
-
The FDA has granted Boehringer Ingelheim Breakthrough Therapy designation to #survodutide for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, and the company has launched two Phase 3 trials (LIVERAGE & LIVERAGE-Cirrhosis) to evaluate this promising therapy. The Breakthrough Therapy designation expedites the development and review of medicines for serious or life-threatening diseases that have shown preliminary clinical evidence indicating substantial improvement over available treatments. In March, the FDA approved the first-ever MASH therapy, Madrigal Pharmaceuticals’ #Rezdiffra (resmetirom). https://lnkd.in/gNAxr94k With increased focus on MASH therapies, this could be a game-changer in liver disease treatment. Read more here: https://lnkd.in/g3rXJUvQ #MASH #LiverHealth #LiverDisease #Cirrhosis #BreakthroughTherapy
-
-
Listen to the latest episode of Unseen Upside: Investments Beyond Their Returns, available now. In it, we explore the global obesity epidemic, how new GLP-1 drugs are offering hope to millions, and what the next generation of these therapeutics could look like. We also follow one woman’s journey to lose weight in an effort to prevent and manage the chronic conditions associated with obesity. Listen here: https://ow.ly/kVS150QZmgl
-
-
Explore the latest trends and breakthroughs on the obesity therapeutics scene in this month's #LifeSciencesAffectsUsAll newsletter! 🗞️ Featuring Eli Lilly and Novo Nordisk (plus many more!), catch up on the latest clinical trials, major investments, and key partnerships in the space. 💫 #ObesityTherapies #HealthInnovation #ClinicalTrials #LifeSciencesNews
Inside Obesity Therapeutics: Trends, Triumphs and Tough Questions
